While bacterial meningitis can be caused by various strains, Meningitis B (MenB) has emerged as the most significant threat in the UK. Since successful vaccination programs have nearly eliminated other forms, MenB now accounts for over 80% of all invasive meningococcal infections.
Thank you for reading this post, don't forget to subscribe!The Complexity of Group B Bacteria
Unlike some diseases caused by a single germ, “Group B” is an umbrella term for a diverse collection of meningococcal B bacteria. This variety makes it particularly difficult to achieve total immunity across the population.
A Tale of Two Generations
The introduction of the MenB vaccine in 2015 created a significant divide in public protection:
- Infants: Those immunized since 2015 have seen a 75% drop in MenB infections.
- The Over-11s: Most people aged 11 and older remain unprotected by the NHS. Unless a family opted for private vaccination, this demographic carries the full risk of the disease.
The High-Risk “Second Peak”
The danger of MenB is not distributed evenly. It follows a “two-peak” pattern:
- Very young children (the highest risk group).
- Older teenagers and university students, where the risk spikes due to close-quarter living and social mixing.
Why Isn’t Everyone Vaccinated?
Despite the risk to teenagers, a national vaccination campaign for this age group was rejected based on cost-effectiveness. This decision was driven by two specific factors:
- High Costs: The vaccine is expensive to purchase and distribute.
- Lack of “Herd Immunity”: Unlike many other vaccines, the MenB shot protects the individual from getting sick, but it does not stop them from carrying or spreading the bacteria to others.
Challenges in Outbreak Control
Vaccines remain a vital tool during localized outbreaks, but they aren’t a “silver bullet.” Health officials must first conduct laboratory tests to ensure the specific type of Group B bacteria causing the outbreak is a match for the available vaccine.
